• Explore /
  • Poster
  • / Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

Abstract Poster

Authors

null

Arvind Dasari

Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

Arvind Dasari , Sara Lonardi , Rocio Garcia-Carbonero , Elena Elez , Takayuki Yoshino , Alberto F. Sobrero , James C. Yao , Pilar Garcia-Alfonso , Judit Kocsis , Antonio Cubillo , Andrea Sartore-Bianchi , Taroh Satoh , Violaine Randrian , Jiri Tomasek , Geoff Chong , Zhao Yang , Rajash Pallai , Iris Carton , Josep Tabernero , Cathy Eng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04322539

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3604)

DOI

10.1200/JCO.2023.41.16_suppl.3604

Abstract #

3604

Poster Bd #

304

Abstract Disclosures

Similar Posters

First Author: Arvind Dasari

First Author: Atsushi Ohtsu

First Author: Atsushi Ohtsu

First Author: Sebastian Stintzing